ONCAlert | 2018 ASCO Annual Meeting
Prostate Cancer Case Studies

E. David Crawford, MD: Influences on Treatment Options

E. David Crawford, MD
Published Online:Jun 18, 2015
Bernie H. is a 75-year-old retired restaurant manager from Queens, New York, who now lives part time in Boca Raton, Florida. He and his wife enjoy boating and fishing.

Metastatic Prostate Cancer: Case 1

Bernie presents with NCCN intermediate-risk prostate cancer. He did very well with the initial therapy; however, a pelvic lymph node signaled recurrence of the disease. This lymph node was likely involved when he had his initial treatment. It took nearly 7 years for it to become detectable both by CT scan and by an elevated PSA level. Had Bernie chosen a radical prostatectomy, a lymph node dissection would likely have identified microscopic disease. Bernie had a second good response to hormonal therapy; however, over the ensuing several years, castrate-resistant disease evolved. The next test that would influence his treatment would be a bone scan. Stratification of men with prostate cancer into risk groups is essential to guide management.

PSA levels currently play a central role in this process, but additional measures including, testosterone levels, time to metastases (particularly those to bone), genomic markers, circulating tumor cells, and patient-reported outcomes, are now being used in clinical trials. There have been many new and exciting developments in the area of prostate cancer imaging. Much effort has been invested in this space, in part, due to the fact that prostate cancer has not seen the benefits of 18F-fluorodeoxyglucose (FDG) PET/CT have seen other malignancies.

CASE 1: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Bernie H. is a 75-year-old retired restaurant manager from Queens, New York, who now lives part time in Boca Raton, Florida. He and his wife enjoy boating and fishing.
  • His prior medical history is notable for mild COPD, which is well controlled with salbutamol, and for arthritis, with total knee replacement in 2007
  • In 2004, he presented to his PCP with symptoms of nocturia × 3. A suspicious digital rectal examination and elevated PSA of 9 mg/mL was noted
  • 12 core biopsies revealed prostate adenocarcinoma of Gleason grade 7 (4 + 3) in 6 of 12 cores on the right side; he was treated with brachytherapy and a short course of 4 months of ADT. Within 6 months, his PSA had declined to undetectable levels (<.02 ng/mL). No further PSA testing was performed until 2011
In December 2011, the patient’s PSA was noted to be 12 ng/mL.
  • Patient was asymptomatic at the time; however, a pelvic CT scan showed an enlarged right iliac lymph node measuring 2.3 cm × 2.2 cm; biopsy of the lesion was consistent with prostate adenocarcinoma
  • Bone scan at the time was negative
  • The patient was started on ADT with 3 months of depot leuprolide and bicalutamide, and his PSA reached a nadir of <.02 ng/mL; testosterone level was <10 ng/mL
  • The patient was asymptomatic, and PSA was monitored every 3 months. His PSA slowly rose from the nadir over the next 4 years in spite of ADT
  • His liver function tests were unremarkable
By March of 2015, the patient had experienced 2 consecutive rises in PSA, first to 16 ng/mL, and then to 27 ng/mL; his testosterone level was <20 ng/dL.
  • CT scan again detected enlargement of the prior iliac lymph node to 2.5 cm × 2.4 cm, and Bernie’s physician confirmed a diagnosis of mCRPC in 2 additional lymph nodes
  • The patient remains asymptomatic, and his oncologist has ascertained progression of his disease
  • A bone scan was not performed, because the patient wanted to return home as soon as possible
  • Bernie and his wife are driving back to New York in their RV in late April. He wants to keep his cancer in check, but is concerned about side effects disrupting their trip
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.